age-related%20macular%20degeneration
AGE-RELATED MACULAR DEGENERATION
Age-related macular degeneration is a common, chronic, progressive, degenerative disease that causes central loss of vision due to abnormalities that occurs in the pigment, neural and vascular layers of the macula.
The macular disorder may have one or more of the following:
- Formation of drusen which are localized deposits of extracellular material usually concentrated in the macula
- Abnormalities in the retinal pigment epithelium (eg hypopigmentation or hyperpigmentation)
- Retinal pigment epithelium and choriocapillaris geographic atrophy
- Neovascular (exudative) maculopathy
Decreased central vision and distortion of seeing straight lines are the most common symptoms.

Follow Up

  • Monocular near vision (using Amsler grid) monitoring should be done in each follow-up exam

Schedule of Follow-up

  • Non-neovascular age-related macular degeneration (AMD)/Intermediate or Advanced AMD in antioxidant vitamin and mineral supplements
    • At 6-24 months after treatment if asymptomatic
    • Advise immediate consultation if new symptoms suggestive of choroidal neovascularization (CNV) occurs
  • Subfoveal neovascular AMD in Ranibizumab therapy
    • Approximately 4 weeks after treatment
    • Subsequent return will be based on the clinical findings
  • Subfoveal neovascular AMD in Pegaptanib sodium therapy
    • Every 6 weeks with retreatments as indicated
  • Subfoveal neovascular AMD after photodynamic therapy (PDT) with Verteporfin
    • Every 3 months until stable, with retreatments as indicated
  • Extrafoveal neovascular AMD after laser photocoagulation therapy
    • At 2-4 weeks after treatment with fundus fluorescein angiography (FFA) and then 4-6 weeks thereafter
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 04 Jul 2016
The risk of band keratopathy may be greatly increased in patients with end-stage renal disease (ESRD), and significant risk factors are iridocyclitis and degenerated eye, according to a Taiwan-based cohort study billed as the largest to ever be conducted on the relationship between the two conditions.
Audrey Abella, 26 Apr 2017
Intravitreous administration of the vascular endothelial growth factor (VEGF) inhibitor ranibizumab does not increase the risk of cardiovascular and cerebrovascular events in patients with diabetic macular edema (DME), according to a recent study.
4 days ago
A number of clinical tumour and treatment parameters, most of which are shown to reflect initial tumour size, appear to contribute to the regression of choroidal melanoma after brachytherapy, a recent study has shown.
Tristan Manalac, 01 May 2018
Eating dark chocolates may have short-term beneficial impacts on vision, according to a recent study, which reports significant improvements in contrast sensitivity and visual acuity following dark vs milk chocolate consumption.